Propel Bio Management, LLC Madrigal Pharmaceuticals, Inc. Transaction History
Propel Bio Management, LLC
- $154 Billion
- Q2 2024
A detailed history of Propel Bio Management, LLC transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Propel Bio Management, LLC holds 43,032 shares of MDGL stock, worth $11.2 Million. This represents 7.82% of its overall portfolio holdings.
Number of Shares
43,032
Previous 43,032
-0.0%
Holding current value
$11.2 Million
Previous $11.5 Billion
4.91%
% of portfolio
7.82%
Previous 6.69%
Shares
2 transactions
Others Institutions Holding MDGL
# of Institutions
296Shares Held
21.9MCall Options Held
757KPut Options Held
370K-
Janus Henderson Group PLC London, X02.49MShares$645 Million0.38% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.06MShares$533 Million7.86% of portfolio
-
Baker Bros. Advisors LP New York, NY1.97MShares$512 Million7.35% of portfolio
-
Rtw Investments, LP New York, NY1.92MShares$497 Million8.96% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny1.85MShares$480 Million39.74% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $4.44B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...